Interferon in oncological practice: Review of interferon biology, clinical applications, and toxicities

被引:401
|
作者
Jonasch, E [1 ]
Haluska, FG [1 ]
机构
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源
ONCOLOGIST | 2001年 / 6卷 / 01期
关键词
interferon; cancer; clinical applications; toxicity; management;
D O I
10.1634/theoncologist.6-1-34
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
For the past 40 years, various forms of interferon (IFN) have been evaluated as therapy in a number of malignant and non-malignant diseases. With the advent of gene cloning, large quantities of pure IFN became available for clinical study. This paper reviews the biology, pharmacology, and clinical applications of IFN formulations most commonly used in oncology. It then reviews the most common side effects seen in patients treated with IFN, and makes recommendations for the management of IFN-induced toxicity. The major oncological indications for IFN include melanoma, renal cell carcinoma, AIDS-related Kaposi's sarcoma, follicular lymphoma, hairy cell leukemia, and chronic myelogenous leukemia. Unfortunately, IFN therapy is associated with significant toxicity, which can be divided into constitutional, neuropsychiatric, hematologic, and hepatic effects. These toxicities have a major impact on the patient's quality of life, and on the physician's ability to optimally treat the patient. Careful attention to all aspects of patient care can result in improved tolerability of this difficult but promising therapy. Conclusion: a better understanding of IFN biology, indications, side effect profiles, and toxicity management will aid in optimizing its use in the treatment of patients with cancer.
引用
收藏
页码:34 / 55
页数:22
相关论文
共 50 条
  • [41] INTERFERON AND RABIES - REVIEW
    TURNER, GS
    IMMUNITAT UND INFEKTION, 1977, 5 (05): : 208 - 213
  • [42] RESEARCH ON INTERFERON - A REVIEW
    TYRRELL, DAJ
    JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 1981, 74 (02) : 145 - 146
  • [43] Requirements and Reality of adjuvant Interferon Therapy in clinical Practice, an internal Audit
    Walter, J.
    Treiber, N.
    Margit, H.
    Scharffetter-Kochanek, K.
    Sindrilaru, A.
    Schneider, L. A.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2015, 13 : 47 - 48
  • [44] Interferon beta in secondary progressive multiple sclerosis -: Daily clinical practice
    Rio, Jordi
    Tintore, Mar
    Nos, Carlos
    Tellez, Neus
    Galan, Ingrid
    Pelayo, Raul
    Montalban, Xavier
    JOURNAL OF NEUROLOGY, 2007, 254 (07) : 849 - 853
  • [45] Results of Interferon-Free HCV Therapy in a Clinical Practice Setting
    Al-Assi, Kenda
    Arif, Farhan
    Horton, Melissa
    Baker, Deborah
    Levine, Cheryl
    Al-Assi, Dana
    Ghalib, Reem
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S162 - S162
  • [48] Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice
    Farrell, R. A.
    Espasandin, M.
    Lakdawala, N.
    Creeke, P. I.
    Worthington, V.
    Giovannoni, G.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 (11) : 1333 - 1340
  • [49] INTERFERON - CURRENT AND FUTURE CLINICAL USES IN INFECTIOUS-DISEASE PRACTICE
    MAIN, J
    HANDLEY, J
    INTERNATIONAL JOURNAL OF STD & AIDS, 1992, 3 (01) : 4 - 9